Loading company…
mustbio develops multi-specific antibody drugs for cancer treatment.
mustbio is a biotechnology company developing antibody-based cancer therapies using a multi-specific antibody platform. Founded in 2021, it is based in Suwon-si, South Korea. In March 2026, it raised KRW 35 billion in Series C funding from Atinum Investment and BNH Investment, with Korea Investment Partners, Premier Partners, Partners Investment, Korea Development Bank, AhnGook Pharm, WONIK Investment Partners and Shinhan Capital returning. The funding will support clinical progress and research and development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in